Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvimopan in Opioid-Induced Postoperative Bowel Dysfunction
NCT00388401Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2002
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alvimopan in postoperative ileus (POI) (3 arms), sponsored by Merck & Co. Primary endpoint: Acceleration of gastrointestinal recovery. Started Jan 2002; status: completed.
02
Drugs
alvimopan
03
Conditions
postoperative ileus (POI)
Beyond the preview
Go deeper on NCT00388401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388401.